Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2928 + azacitidine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
TQB2928 + azacitidine is an investigational combination therapy being studied for the treatment of hematological malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). TQB2928 is a fully humanized IgG4 monoclonal antibody that targets CD47, a cell surface protein involved in immune evasion by cancer cells. By blocking CD47, TQB2928 promotes phagocytosis of tumor cells by macrophages. Azacitidine is a nucleoside metabolism inhibitor and DNA methyltransferase inhibitor that reduces DNA methylation and alters gene expression, leading to the production of normal blood cells and death of abnormal cells. The combination aims to enhance anti-tumor activity through complementary mechanisms: immune checkpoint inhibition (TQB2928) and epigenetic modulation/cytotoxicity (azacitidine)[5][6][7].
- Brand names
- Vidaza (for azacitidine)
02
Targets
CD47 (Cluster of Differentiation 47)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on TQB2928 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2928 + azacitidine.